Ftse Mib
35.398,82
-0,03%
DAX
18.704,42
-0,11%
S&P 500
5.303,27
0,12%
NASDAQ
16.685,97
-0,07%
Bitcoin
66.408,43
0,20%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ BeiGene Ltd (BGNE) BeiGene Ltd (BGNE) Notizie

BGNE

BeiGene (BGNE)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:BGNE
DataOraFonteTitoloSimboloCompagnia
16/05/202400:10Business WireEHA2024: BeiGene präsentiert neues Hämatologie-Portfolio und Pipeline-DatenNASDAQ:BGNEBeiGene Ltd
15/05/202423:50Business WireBeiGene présente de nouvelles données de portefeuille et de pipeline d'hématologie à l'EHA2024NASDAQ:BGNEBeiGene Ltd
14/05/202422:01Business WireBeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024NASDAQ:BGNEBeiGene Ltd
09/05/202421:03Business WireBeiGene meldet Finanzergebnisse für das erste Quartal 2024 und aktuelle GeschäftsentwicklungenNASDAQ:BGNEBeiGene Ltd
09/05/202415:38Business Wireベイジーン、2024年第1四半期決算および事業に関する最新情報を発表NASDAQ:BGNEBeiGene Ltd
09/05/202403:02Business WireBeiGene公布2024年第一季財務業績和最新業務情況NASDAQ:BGNEBeiGene Ltd
09/05/202401:03Business WireBeiGene présente ses résultats financiers du premier trimestre 2024 et ses dernières nouvelles commercialesNASDAQ:BGNEBeiGene Ltd
08/05/202412:00Business WireBeiGene Reports First Quarter 2024 Financial Results and Business UpdatesNASDAQ:BGNEBeiGene Ltd
26/04/202416:34Business WireBeiGene Demonstrates Global Progress in 2023 Responsible Business & Sustainability ReportNASDAQ:BGNEBeiGene Ltd
25/04/202413:11Business WireGlobaler Onkologie-Innovator BeiGene präsentiert auf der ASCO-Jahrestagung 2024 neue Daten aus dem gesamten Portfolio für Hämatologie und solide TumoreNASDAQ:BGNEBeiGene Ltd
25/04/202413:10Business WireBeiGene, innovateur mondial en oncologie, présente de nouvelles données sur l’ensemble de son portefeuille en hématologie et en tumeurs solides lors de la réunion annuelle de l’ASCO 2024NASDAQ:BGNEBeiGene Ltd
24/04/202422:01Business WireGlobal Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual MeetingNASDAQ:BGNEBeiGene Ltd
24/04/202401:31Business WireBeiGene reçoit l’approbation de la Commission européenne pour le tislelizumab dans le traitement du cancer du poumon non à petites cellulesNASDAQ:BGNEBeiGene Ltd
24/04/202401:31Business WireBeiGene erhält von der EU-Kommission die Zulassung für Tislelizumab zur Behandlung von nicht kleinzelligem LungenkrebsNASDAQ:BGNEBeiGene Ltd
23/04/202412:00Business WireBeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung CancerNASDAQ:BGNEBeiGene Ltd
16/03/202416:18Business WireBeiGene、化学療法後の進行性または転移性食道扁平上皮癌の治療のためのTEVIMBRA®のFDA承認取得NASDAQ:BGNEBeiGene Ltd
15/03/202422:13Business Wire百濟神州喜獲FDA批准，TEVIMBRA®將用於晚期或轉移性食管鱗狀細胞癌在化療後的治療NASDAQ:BGNEBeiGene Ltd
15/03/202421:02Business WireBeiGene reçoit l'approbation de la FDA pour TEVIMBRA® dans le traitement du carcinome épidermoïde de l’œsophage avancé ou métastatique après une chimiothérapieNASDAQ:BGNEBeiGene Ltd
15/03/202407:06Business WireBeiGene erhält FDA-Zulassung für TEVIMBRA ® zur Behandlung des fortgeschrittenen oder metastasierten Plattenepithelkarzinoms der Speiseröhre nach vorheriger ChemotherapieNASDAQ:BGNEBeiGene Ltd
14/03/202421:28Business WireBeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior ChemotherapyNASDAQ:BGNEBeiGene Ltd
14/03/202415:23Business Wireマックス財団、ベイジーン、ベイジーン財団の協力により、低・中所得国の慢性リンパ性白血病患者にBRUKINSA®を初回投与NASDAQ:BGNEBeiGene Ltd
14/03/202410:31Business WireThe Max Foundation、BeiGene和BeiGene Foundation共同向中低收入國家的慢性淋巴性白血病病患提供首批BRUKINSA®藥物NASDAQ:BGNEBeiGene Ltd
13/03/202420:01Business WireLes premières doses de BRUKINSA® sont administrées à des patients atteints de leucémie lymphoïde chronique dans des pays à revenus faibles et moyens, grâce à la collaboration de la Max Foundation, de BeiGene et de la BeiGene FoundationNASDAQ:BGNEBeiGene Ltd
13/03/202420:01Business WireErste Dosen von BRUKINSA ® für Patienten mit chronischer lymphatischer Leukämie in Ländern mit niedrigem und mittlerem Einkommen im Rahmen der Zusammenarbeit von The Max Foundation, BeiGene und der BeiGene FoundationNASDAQ:BGNEBeiGene Ltd
13/03/202413:00Business WireFirst Doses of BRUKINSA® provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene FoundationNASDAQ:BGNEBeiGene Ltd
07/03/202423:19Business WireBeiGene Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular LymphomaNASDAQ:BGNEBeiGene Ltd
06/03/202412:00Business WireBeiGene to Present Clinical and Preclinical Data from Broad Portfolio and Pipeline at AACR Annual Meeting 2024NASDAQ:BGNEBeiGene Ltd
29/02/202417:17Business Wireベイジーン、2023年第4・四半期および通期決算と事業に関する最新情報を発表NASDAQ:BGNEBeiGene Ltd
29/02/202416:00Business WireBeiGene Announces New Efficacy Analysis Comparing BRUKINSA® vs Acalabrutinib in Relapsed or Refractory Chronic Lymphocytic LeukemiaNASDAQ:BGNEBeiGene Ltd
29/02/202401:56Business WireBeiGene publie ses résultats financiers du quatrième trimestre et de l’exercice 2023 et ses mises à jour commercialesNASDAQ:BGNEBeiGene Ltd
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:BGNE

La tua Cronologia

EU
AXHLA
AXA Home Loan SFH 0.050%...
AMEX
BSCE
Invesco Bulletshares 202...
USOTC
GRNCY
Graincorp (PK)
USOTC
LECBF
Lepanto Cons Mng (CE)
TSXV
GFM.H
GFM Resources
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network